Un cas d’atteinte démyélinisante combinée centrale et périphérique

van der Meijs, 2002, Incidence of enhancement of the trigeminal nerve on MRI in patients with multiple sclerosis, Mult Scler Houndmills Basingstoke Engl, 8, 64, 10.1191/1352458502ms775oa Vural, 2016, Fulminant central plus peripheral nervous system demyelination without antibodies to neurofascin, Can J Neurol Sci, 43, 149, 10.1017/cjn.2015.238 Wang, 2018, The clinical features of combined central and peripheral demyelination in Chinese patients, J Neuroimmunol, 317, 32, 10.1016/j.jneuroim.2018.02.006 Cortese, 2016, Combined central and peripheral demyelination: clinical features, diagnostic findings, and treatment, J Neurol Sci, 363, 182, 10.1016/j.jns.2016.02.022 Ogata, 2016, A nationwide survey of combined central and peripheral demyelination in Japan, J Neurol Neurosurg Psychiatry, 87, 29 Zephir, 2008, Relapsing demyelinating disease affecting both the central and peripheral nervous systems, J Neurol Neurosurg Psychiatry, 79, 1032, 10.1136/jnnp.2006.108290 Devaux, 2016, Neurofascin-155 IgG4 in chronic inflammatory demyelinating polyneuropathy, Neurology, 86, 800, 10.1212/WNL.0000000000002418 Delmont, 2017, Autoantibodies to nodal isoforms of neurofascin in chronic inflammatory demyelinating polyneuropathy, Brain, 140, 1851, 10.1093/brain/awx124 Kawamura, 2013, Anti-neurofascin antibody in patients with combined central and peripheral demyelination, Neurology, 81, 714, 10.1212/WNL.0b013e3182a1aa9c